PT - JOURNAL ARTICLE AU - Gao, Lu AU - Dhilipkannah, Pushpa AU - Holden, Van K AU - Deepak, Janaki AU - Sachdeva, Ashutosh AU - Todd, Nevins W AU - Stass, Sanford A AU - Jiang, Feng TI - Differential Non-Coding RNA Profiles for Lung Cancer Early Detection in African and White Americans AID - 10.1101/2024.03.27.24304977 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.27.24304977 4099 - http://medrxiv.org/content/early/2024/03/29/2024.03.27.24304977.short 4100 - http://medrxiv.org/content/early/2024/03/29/2024.03.27.24304977.full AB - Introduction Lung cancer leads in cancer-related deaths. Disparities are observed in lung cancer rates, with African Americans (AAs) experiencing disproportionately higher incidence and mortality compared to other ethnic groups. Non-coding RNAs (ncRNAs) play crucial roles in lung tumorigenesis. Our objective was to identify ncRNA biomarkers associated with the racial disparity in lung cancer.Methods Using droplet digital PCR, we examined 93 lung-cancer-associated ncRNAs in the plasma and sputum samples from AA and White American (WA) participants, which included 118 patients and 92 cancer-free smokers. Subsequently, we validated our results with a separate cohort comprising 56 cases and 72 controls.Results In the AA population, plasma showed differential expression of ten ncRNAs, while sputum revealed four ncRNAs when comparing lung cancer patients to the control group. In the WA population, the plasma displayed eleven ncRNAs, and the sputum had five ncRNAs showing differential expression between the lung cancer patients and the control group. For AAs, we identified a three-ncRNA panel (plasma miRs-147b, 324-3p, 422a) diagnosing lung cancer in AAs with 86% sensitivity and 89% specificity. For WAs, a four-ncRNA panel was developed, comprising sputum miR-34a-5p and plasma miRs-103-3p, 126-3p, 205-5p, achieving 88% sensitivity and 87% specificity. These panels remained effective across different stages and histological types of lung tumors and were validated in the independent cohort.Conclusions The ethnicity-related ncRNA signatures have promise as biomarkers to address the racial disparity in lung cancer.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.medschool.umaryland.edu/profiles/jiang-feng/ Funding StatementNCIAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the Institutional Review Board of the University of Maryland Baltimore.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.medschool.umaryland.edu/profiles/jiang-feng/ https://www.medschool.umaryland.edu/profiles/jiang-feng/